In the present study, we examined whether intervention with a senolytic therapy (a HSP90 inhibitor), a senostatic therapy (an ASK1 inhibitor), or combined treatments would provide effective protection against the development of CKD caused by ongoing diabetes and acute ischemic injury. This evidence concerns the gene MAP3K5 and diabetes mellitus.